AR037741A1 - Uso de inhibidores de la fosfodiesterasa iv - Google Patents
Uso de inhibidores de la fosfodiesterasa ivInfo
- Publication number
- AR037741A1 AR037741A1 ARP020103824A ARP020103824A AR037741A1 AR 037741 A1 AR037741 A1 AR 037741A1 AR P020103824 A ARP020103824 A AR P020103824A AR P020103824 A ARP020103824 A AR P020103824A AR 037741 A1 AR037741 A1 AR 037741A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- independently
- hal
- atoms
- cooa
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 26
- 125000004429 atom Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- -1 methylenedioxy Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10150517A DE10150517A1 (de) | 2001-10-12 | 2001-10-12 | Verwendung von Phosphodiesterase IV-Inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037741A1 true AR037741A1 (es) | 2004-12-01 |
Family
ID=7702358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103824A AR037741A1 (es) | 2001-10-12 | 2002-10-11 | Uso de inhibidores de la fosfodiesterasa iv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040235845A1 (enExample) |
| EP (1) | EP1435958A1 (enExample) |
| JP (1) | JP2005505604A (enExample) |
| KR (1) | KR20050028900A (enExample) |
| CN (1) | CN1564687A (enExample) |
| AR (1) | AR037741A1 (enExample) |
| AU (1) | AU2002338734B2 (enExample) |
| CA (1) | CA2460135C (enExample) |
| CZ (1) | CZ2004457A3 (enExample) |
| DE (1) | DE10150517A1 (enExample) |
| HU (1) | HUP0401641A3 (enExample) |
| MX (1) | MXPA04002639A (enExample) |
| NO (1) | NO20041938L (enExample) |
| SK (1) | SK1652004A3 (enExample) |
| WO (1) | WO2003032993A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023253A1 (en) * | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| US20080227790A1 (en) * | 2004-02-04 | 2008-09-18 | Altana Pharma Ag | Pyridazinone Derivatives and their Use as Pde4 Inhibitors |
| AU2005210042B2 (en) | 2004-02-04 | 2011-04-21 | Takeda Gmbh | 2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors |
| MX2007010560A (es) | 2005-03-08 | 2008-02-21 | Nycomed Gmbh | Roflumilast para el tratamiento de diabetes mellitus. |
| DE102005055354A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| UA100497C2 (ru) | 2006-09-07 | 2013-01-10 | Никомед Гмбх | Комбинированное лечение сахарного диабета |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| RU2626677C1 (ru) * | 2016-03-09 | 2017-07-31 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Применение фармацевтической композиции 2-морфолино-5-фенил-6н-1,3,4-тиадиазина с аскорбиновой кислотой в качестве средства коррекции аллоксанового сахарного диабета |
| MA59016B1 (fr) * | 2022-12-30 | 2024-09-30 | Université Ibn Tofail | Nouveaux composés hétérocycliques de type 1,3,4-thiadiazines pour le traitement du diabète de type 2 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134893A1 (de) * | 1991-10-23 | 1993-04-29 | Merck Patent Gmbh | Thiadiazinone |
| DE4310699A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Thiadiazinone |
| US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| DE19502699A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | Arylalkyl-thiadiazinone |
| DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
| DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
| GB9525262D0 (en) * | 1995-12-11 | 1996-02-07 | Bayer Ag | Heterocyclylcarbonyl substituted benzofuranyl-ureas |
| DE19604388A1 (de) * | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
| US5948911A (en) * | 1998-11-20 | 1999-09-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives |
-
2001
- 2001-10-12 DE DE10150517A patent/DE10150517A1/de not_active Withdrawn
-
2002
- 2002-09-19 WO PCT/EP2002/010507 patent/WO2003032993A1/de not_active Ceased
- 2002-09-19 CA CA2460135A patent/CA2460135C/en not_active Expired - Fee Related
- 2002-09-19 SK SK165-2004A patent/SK1652004A3/sk not_active Application Discontinuation
- 2002-09-19 HU HU0401641A patent/HUP0401641A3/hu unknown
- 2002-09-19 KR KR1020047005415A patent/KR20050028900A/ko not_active Withdrawn
- 2002-09-19 CZ CZ2004457A patent/CZ2004457A3/cs unknown
- 2002-09-19 MX MXPA04002639A patent/MXPA04002639A/es not_active Application Discontinuation
- 2002-09-19 CN CNA028198638A patent/CN1564687A/zh active Pending
- 2002-09-19 US US10/492,367 patent/US20040235845A1/en not_active Abandoned
- 2002-09-19 EP EP02777150A patent/EP1435958A1/de not_active Withdrawn
- 2002-09-19 AU AU2002338734A patent/AU2002338734B2/en not_active Ceased
- 2002-09-19 JP JP2003535796A patent/JP2005505604A/ja active Pending
- 2002-10-11 AR ARP020103824A patent/AR037741A1/es not_active Application Discontinuation
-
2004
- 2004-05-11 NO NO20041938A patent/NO20041938L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK1652004A3 (sk) | 2005-05-05 |
| HUP0401641A2 (hu) | 2004-11-29 |
| CA2460135C (en) | 2010-08-24 |
| MXPA04002639A (es) | 2004-06-07 |
| KR20050028900A (ko) | 2005-03-23 |
| US20040235845A1 (en) | 2004-11-25 |
| CA2460135A1 (en) | 2003-04-24 |
| EP1435958A1 (de) | 2004-07-14 |
| WO2003032993A1 (de) | 2003-04-24 |
| HUP0401641A3 (en) | 2007-02-28 |
| JP2005505604A (ja) | 2005-02-24 |
| AU2002338734B2 (en) | 2007-11-08 |
| NO20041938L (no) | 2004-05-11 |
| CZ2004457A3 (cs) | 2005-04-13 |
| DE10150517A1 (de) | 2003-04-17 |
| CN1564687A (zh) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037741A1 (es) | Uso de inhibidores de la fosfodiesterasa iv | |
| AR036075A1 (es) | Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| AR048346A1 (es) | Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central. | |
| AR037743A1 (es) | Inhibidores de fosfodiesterasa de tipo 4, combinaciones y usos de los mismos | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| AR053773A1 (es) | Procedimientos para preparar compuestos de indazol | |
| AR049103A1 (es) | Derivados de piridazinona metodos para producirlos y su uso como productos farmaceuticos | |
| PE20000426A1 (es) | Uso de dihidropirimidinas como medicamento y nuevas sustancias | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| AR076810A1 (es) | Compuestos anticancerigenos de amino pirimidina | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| CO5271658A1 (es) | Antagonistas del factor liberador de corticotropina | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR044629A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| AR050436A1 (es) | Inhibidores de azaindol de mtp y apob | |
| AR062791A1 (es) | Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico | |
| MXPA05008584A (es) | Compuestos heterociclicos utiles como activadores de nurr-1. | |
| AR026352A1 (es) | Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |